This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.
Beyond the Joint: Cross-Specialty Solutions for Advancing TGCT Patient Care
Emerging Evidence in Focus: Interpreting Data on Next-Generation CSF1R TKIs
Overview
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, it is the policy of Global Learning Collaborative (GLC) that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Global Learning Collaborative (GLC) has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity.
The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months.
Chair:
A.J. (Hans) Gelderblom, MD, PhD
Chair of Department of Medical Oncology
Leiden University Medical Center
Leiden, The NetherlandsDr. Gelderblom has no relevant relationships to disclose.
Faculty:
Michiel van de Sande, MD, PhD
Professor, Orthopedic Oncology
Leiden University Medical Center
Leiden, The Netherlands
Dr. van de Sande has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Advisor/Consultant: Deciphera, Implantcast GmbH, Merck, SynOx
Contracted Researcher: Implantcast GmbH
Chelsea Cole, MD
Director, Sports and Musculoskeletal Medicine
UT Southwestern Medical Center
Dallas, TX
Dr. Cole has no relevant relationships to disclose.
Reviewers/Content Planners/Authors:- Cindy Davidson has no relevant relationships to disclose.
- Bing-E Xu, PhD has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Improve early recognition of tenosynovial giant cell tumor (TGCT) through disease understanding, accurate subtype differentiation, and identification of disease characteristics that warrant specialist referral
- Critically assess clinical trial evidence, including functional endpoints and patient-reported outcomes, to understand the impact of systemic therapy in TGCT
- Utilize clinical trial data and patient-centered outcomes to select the most appropriate TGCT treatment strategy based on disease presentation and functional impact
- Develop a comprehensive plan for managing adverse events associated with CSF1R inhibitors to ensure treatment continuity and patient safety
Target Audience
This activity has been designed to meet the educational needs of medical oncologists and orthopedic surgeons as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with tenosynovial giant cell tumor (TGCT).
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-25-145-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). Approval is valid until 12/15/26. PAs should claim only the credit commensurate with the extent of their participation in the activity. Provider(s)/Educational Partner(s)
AGILE – Academy for Global Interprofessional Learning and Education – designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes.Commercial Support
This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited Reproduction of this material is not permitted without written permission from the copyright owner.
Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.”System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
